Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 10/2017

01-10-2017 | Original Article

Why does measles persist in Europe?

Author: P. Plans-Rubió

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 10/2017

Login to get access

Abstract

Several reasons may explain why measles was not eliminated by 2015 and continues to persist in Europe, including low measles vaccination coverage, low anti-measles herd immunity levels, and the mobility of individuals with measles across Europe. The study assessed the mean measles vaccination coverage in the European Union and the WHO European region with one and two doses of measles vaccine from 1980 to 2015, and the prevalence of vaccine-induced protected individuals and anti-measles herd immunity levels in the WHO European region during 2000–2015. The study found that measles vaccination coverage with two doses of vaccine was <90% in the European Union and the WHO European region from 1995 to 2015. In the WHO European region, the two-dose measles vaccination coverage during the 2000–2015 period was <95% in 41 countries (79%), and the prevalence of vaccine-induced protected individuals in the target vaccination population was lower than the herd immunity threshold of 94.4% in 33 countries (63%). The additional vaccination coverage required to establish herd immunity in these countries ranged from 0.2% to 18%. Two of the factors explaining measles persistence in Europe in 2015 were the two-dose measles vaccination coverage <95% and the prevalence of individuals with vaccine-induced protection of <94.4% in most countries of the WHO European region during the 2000–2015 period. Screening and vaccination programs should be developed to detect and immunize susceptible individuals in areas and population groups without anti-measles herd immunity in all European countries.
Literature
11.
go back to reference Anderson RM, May RM (1991) Infectious diseases of humans: dynamics and control. Oxford University Press, Oxford Anderson RM, May RM (1991) Infectious diseases of humans: dynamics and control. Oxford University Press, Oxford
12.
go back to reference Gay NJ (2004) The theory of measles elimination: implications for the design of elimination strategies. J Infect Dis 189 [Suppl 1]:S27−S35CrossRefPubMed Gay NJ (2004) The theory of measles elimination: implications for the design of elimination strategies. J Infect Dis 189 [Suppl 1]:S27−S35CrossRefPubMed
13.
go back to reference Plans-Rubió P (2012) Evaluation of the establishment of herd immunity in the population by means of serological surveys and vaccination coverage. Hum Vaccin Immunother 8:184–188CrossRefPubMed Plans-Rubió P (2012) Evaluation of the establishment of herd immunity in the population by means of serological surveys and vaccination coverage. Hum Vaccin Immunother 8:184–188CrossRefPubMed
14.
go back to reference Plans-Rubió P (2010) Prevalence of antibodies associated with herd immunity: a new indicator to evaluate the establishment of herd immunity and to decide immunisation strategies. Med Decis Making 30:438–443CrossRef Plans-Rubió P (2010) Prevalence of antibodies associated with herd immunity: a new indicator to evaluate the establishment of herd immunity and to decide immunisation strategies. Med Decis Making 30:438–443CrossRef
15.
go back to reference Hinman AR, Urquhart GA, Strikas RA (2007) Immunization information systems. National Vaccine Advisory Committee progress report, 2007. J Public Health Manag Pract 13:553–558CrossRefPubMed Hinman AR, Urquhart GA, Strikas RA (2007) Immunization information systems. National Vaccine Advisory Committee progress report, 2007. J Public Health Manag Pract 13:553–558CrossRefPubMed
16.
go back to reference Muller CP, Kremer JR, Best JM, Dourado I, Triki H, Reef S, WHO Steering Committee for Measles and Rubella (2007) Reducing global disease burden of measles and rubella: report of the WHO Steering Committee on research related to measles and rubella vaccines and vaccination, 2005. Vaccine 25:1–9CrossRefPubMed Muller CP, Kremer JR, Best JM, Dourado I, Triki H, Reef S, WHO Steering Committee for Measles and Rubella (2007) Reducing global disease burden of measles and rubella: report of the WHO Steering Committee on research related to measles and rubella vaccines and vaccination, 2005. Vaccine 25:1–9CrossRefPubMed
17.
go back to reference Plans P (2013) New preventive strategy to eliminate measles, mumps and rubella from Europe based on the serological assessment of herd immunity levels in the population. Eur J Clin Microbiol Infect Dis 32:961–996CrossRefPubMed Plans P (2013) New preventive strategy to eliminate measles, mumps and rubella from Europe based on the serological assessment of herd immunity levels in the population. Eur J Clin Microbiol Infect Dis 32:961–996CrossRefPubMed
18.
go back to reference Rota PA, Brown K, Mankertz A, Santibanez S, Shulga S, Muller CP et al (2011) Global distribution of measles genotypes and measles molecular epidemiology. J Infect Dis 204 [Suppl 1]:S514–S523CrossRefPubMed Rota PA, Brown K, Mankertz A, Santibanez S, Shulga S, Muller CP et al (2011) Global distribution of measles genotypes and measles molecular epidemiology. J Infect Dis 204 [Suppl 1]:S514–S523CrossRefPubMed
19.
go back to reference Pannuti CS, Morello RJ, De Moraes JC, Curti SP, Afonso AMS, Camargo MCC, De Souza VAUF (2004) Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic. Clin Diagn Lab Immunol 11:119–122PubMedPubMedCentral Pannuti CS, Morello RJ, De Moraes JC, Curti SP, Afonso AMS, Camargo MCC, De Souza VAUF (2004) Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic. Clin Diagn Lab Immunol 11:119–122PubMedPubMedCentral
20.
go back to reference Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H (2008) Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis 197:950–956CrossRefPubMed Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H (2008) Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis 197:950–956CrossRefPubMed
Metadata
Title
Why does measles persist in Europe?
Author
P. Plans-Rubió
Publication date
01-10-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 10/2017
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-017-3011-y

Other articles of this Issue 10/2017

European Journal of Clinical Microbiology & Infectious Diseases 10/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.